Novartis AG Price Target Raised to $104.00 at Leerink Swann (NVS)
Stock analysts at Leerink Swann lifted their price objective on shares of Novartis AG (NYSE:NVS) from $93.00 to $104.00 in a report issued on Wednesday. The firm currently has an “outperform” rating on the stock. Leerink Swann’s price objective points to a potential upside of 15.20% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group upgraded shares of Novartis AG from a “hold” rating to a “buy” rating in a research note on Friday, May 2nd. Separately, analysts at JPMorgan Chase & Co. upgraded shares of Novartis AG from a “neutral” rating to an “overweight” rating in a research note on Tuesday, April 29th. Finally, analysts at Natixis downgraded shares of Novartis AG from a “buy” rating to a “neutral” rating in a research note on Thursday, April 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $93.50.
Shares of Novartis AG (NYSE:NVS) opened at 90.28 on Wednesday. Novartis AG has a 1-year low of $67.67 and a 1-year high of $90.43. The stock’s 50-day moving average is $86.93 and its 200-day moving average is $82.09. The company has a market cap of $220.9 billion and a P/E ratio of 23.03.
Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.31 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.27 by $0.04. The company had revenue of $14.02 billion for the quarter, compared to the consensus estimate of $14.25 billion. During the same quarter last year, the company posted $1.32 earnings per share. Novartis AG’s revenue was up .0% compared to the same quarter last year. On average, analysts predict that Novartis AG will post $5.27 earnings per share for the current fiscal year.
Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.